Meningococcal Vaccines Market Outlook From 2026 To 2030: Key Growth Factors And Future Opportunities
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Meningococcal Vaccines Market Poised To Hit $6.58 Billion By 2030 With A 9.1% CAGR
The meningococcal vaccines market size has experienced robust growth in recent years. It is projected to increase from $4.26 billion in 2025 to $4.65 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.3%. The expansion observed in the historical period can be attributed to the availability of meningococcal conjugate vaccines, an escalation in the occurrence of meningitis outbreaks, governmental immunization initiatives, expanding pediatric vaccination rates, and enhanced public health funding.
The meningococcal vaccines market is anticipated to experience robust expansion in the coming years. It is projected to reach $6.58 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 9.1%. This growth during the forecast period can be attributed to several factors, including advancements in vaccine technology, the expansion of global immunization programs, a rise in awareness regarding meningococcal disease, the formation of strategic partnerships and collaborations, and an increase in vaccination initiatives targeting adolescents and young adults. Key trends anticipated within this period involve the expansion of pediatric vaccination programs, the development of broad-spectrum meningococcal vaccines, increased government-led immunization efforts, heightened awareness concerning meningococcal disease prevention, and the growth of vaccination campaigns in schools and colleges.
Get A Free Sample Report With In-Depth Market Insights:
Meningococcal Vaccines Market Demand Drivers Opening New Revenue Streams
The meningococcal vaccine market is anticipated to grow, driven by an uptick in healthcare spending. Healthcare includes institutions providing residential care, nursing facilities, and intermediate care for individuals with mental illnesses or intellectual disabilities. A significant discussion point has been the high cost of newer vaccine generations compared to previous ones, prompting scrutiny into whether their benefits justify their prices. Consequently, assessing the comprehensive social and economic advantages of vaccination is becoming an increasingly vital area of study in the literature concerning vaccine valuation. For instance, an article published by the American Medical Association in April 2025 indicated that U.S. health spending increased by 7.5% in 2023, reaching $4.9 trillion or $14,570 per capita. This expansion rate is considerably higher than the 4.6% increase recorded in 2022. Therefore, the expanding healthcare expenditure is fueling the growth of the meningococcal vaccine market.
Meningococcal Vaccines Market Breakdown By Product Type And Application
The meningococcal vaccines market covered in this report is segmented –
1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine
2) By Serotype: Men Acwy, Men B/Bc, Men C
3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults
4) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Channels
5) By End user: Hospitals, Research, Academic Institutes
Subsegments:
1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine
2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine
3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines
Meningococcal Vaccines Market Trends Powering Strategic Industry Growth
Major companies in the meningococcal vaccines market are developing new vaccines to prevent various serogroups, aiming to boost their market profitability. Meningococcal vaccines are designed as preventive measures to shield individuals from infections caused by specific serogroups of the Neisseria meningitidis bacteria. For instance, in October 2023, Pfizer Inc., a US-based pharmaceutical company, obtained FDA approval for its vaccine, PENBRAYA. With extensive serogroup coverage, PENBRAYA is the most comprehensive U.S.-approved meningococcal vaccine, protecting against groups A, B, C, W, and Y. The FDA approval is supported by robust Phase 2 and 3 trial data, confirming non-inferior immunogenicity compared to Trumenba + Menveo across all serogroups, alongside a favorable safety profile. Pfizer’s September 2022 announcement had previously revealed positive outcomes from a Phase 3 trial, which assessed PENBRAYA’s safety, tolerability, and immunogenicity against existing licensed meningococcal vaccines.
Meningococcal Vaccines Market Company Landscape And Competitive Strategy
Major companies operating in the meningococcal vaccines market are Pfizer Inc.,GlaxoSmithKline plc,Sanofi Pasteur,Merck & Co. Inc.,Serum Institute of India Pvt. Ltd.,Bio-Manguinhos,Walvax Biotechnology Co. Ltd.,Bharat Biotech,Panacea Biotec Ltd.,CSL Limited,Minhai Biotechnology Co. Ltd.,Hualan Biological Engineering Inc.,Shenzhen Kangtai Biological Products Co. Ltd.,Chongqing Zhifei Biological Products Co. Ltd.,Incepta Pharmaceuticals Ltd.,Biological E. Limited,Biokangtai,Biomed Pvt Ltd.,Biocine SCL,Bavarian Nordic A/S
View The Full Meningococcal Vaccines Market Report:
Meningococcal Vaccines Market Regional Analysis And Leading Geography
North America was the largest region in the meningococcal vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
